What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?

Mishra, 2006, To what extent do real life practice studies differ from randomized controlled trials in lower urinary tract symptoms/benign prostatic hyperplasia?, Curr Opin Urol, 16, 1, 10.1097/01.mou.0000193369.99446.ac Michel, 2000, Treatment satisfaction of patients with lower urinary tract symptoms: randomised controlled trials vs. real life practice, Eur Urol, 38, 40, 10.1159/000052400 Eri, 1992, Patient recruitment to and cost of a prospective trial of medical treatment for benign prostatic hyperplasia, Eur Urol, 22, 9, 10.1159/000474714 van Leeuwen, 2006, The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms, Eur Urol, 50, 440, 10.1016/j.eururo.2006.05.014 Nickel, 1998, Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group, Br J Urol, 81, 383, 10.1046/j.1464-410x.1998.00554.x Gormley, 1992, The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group, N Engl J Med, 327, 1185, 10.1056/NEJM199210223271701 1993, Finasteride (MK-906) in the treatment of benign prostatic hyperplasia, Prostate, 22, 291, 10.1002/pros.2990220403 McConnell, 1998, The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia, N Engl J Med, 338, 557, 10.1056/NEJM199802263380901 Boyle, 1996, Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials, Urology, 48, 398, 10.1016/S0090-4295(96)00353-6 Bramson, 1997, Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR, J Pharmacol Exp Ther, 282, 1496 Clark, 1999, Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel, dual 5 alpha reductase inhibitor, J Urol, 161, 268, 10.1097/00005392-199904020-00076 McConnell, 1992, Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia, J Clin Endocrinol Metab, 74, 505, 10.1210/jc.74.3.505 Clark, 2004, Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor, J Clin Endocrinol Metab, 89, 2179, 10.1210/jc.2003-030330 Roehrborn, 2002, Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia, Urology, 60, 434, 10.1016/S0090-4295(02)01905-2 Desgrandchamps, 2006, Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice, BJU Int, 98, 83, 10.1111/j.1464-410X.2006.06241.x Shakir, 2001, Finasteride and tamsulosin used in benign prostatic hypertrophy: a review of the prescription-event monitoring data, BJU Int, 87, 789, 10.1046/j.1464-410x.2001.02207.x Hutchison, 2007, The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries, Eur Urol, 51, 207, 10.1016/j.eururo.2006.06.012 AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 3. Results of the treatment outcomes analyses. Available at www.auanet.org. Accessed 22 January 2007. Souverein, 2005, Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: a population-based cohort study in the Netherlands, Eur Urol, 47, 505, 10.1016/j.eururo.2004.11.001 Lowe, 2003, Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia, Urology, 61, 791, 10.1016/S0090-4295(02)02548-7 Lam, 2003, Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up, Urology, 61, 354, 10.1016/S0090-4295(02)02149-0 Roehrborn, 2004, Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia, J Urol, 171, 1194, 10.1097/01.ju.0000112918.74410.94 Debruyne, 2004, Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia, Eur Urol, 46, 488, 10.1016/j.eururo.2004.05.008 Schulman, 2006, Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia, BJU Int, 97, 73, 10.1111/j.1464-410X.2005.05909.x McConnell, 2003, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia, N Engl J Med, 349, 2387, 10.1056/NEJMoa030656 Boyle, 2004, 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery, Eur Urol, 45, 620, 10.1016/j.eururo.2003.09.012